Response to nitric oxide in term and preterm infants

Area of Science:

• Neonatal Medicine
• Pediatric Pulmonology
• Critical Care

Background:

• Persistent pulmonary hypertension of the newborn (PPHN) and severe respiratory failure necessitate advanced treatments.
• Inhaled nitric oxide (NO) is a selective pulmonary vasodilator used in neonates.
• Optimal dosing strategies for inhaled NO require further investigation, especially in diverse neonatal populations.

Purpose of the Study:

• To evaluate the efficacy of different inhaled nitric oxide (NO) concentrations (10, 20, and 40 ppm) in neonates with respiratory failure.
• To determine the optimal NO dosage based on patient diagnosis and gestational age.
• To assess the impact of NO on the oxygenation index (OI) in a cohort of critically ill infants.

Main Methods:

• A prospective study involving 30 infants requiring supplemental oxygen (>0.5 FiO2).
• Administration of inhaled nitric oxide (NO) at three dose levels: 10 ppm, 20 ppm, and 40 ppm.
• Measurement of the oxygenation index (OI) to assess treatment response at each NO level.

Main Results:

• A positive response to inhaled NO (reduction in OI) was observed in 29 out of 30 infants.
• The median reduction in OI was 33%, with 20 infants showing a >20% decrease.
• Infants with pulmonary interstitial emphysema (PIE) and those <28 weeks gestational age showed a better response to 40 ppm NO.

Conclusions:

• Inhaled nitric oxide (NO) is effective in improving oxygenation in a majority of neonates with respiratory failure.
• Higher NO concentrations (up to 40 ppm) may be particularly beneficial for very premature infants and those with PIE.
• Individualized NO dosage titration is crucial for optimizing therapeutic outcomes in neonates.